Vor Biopharma (VOR) Profit After Tax (2020 - 2026)

Vor Biopharma (VOR) has reported Profit After Tax for 7 consecutive years, with -$747000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 97.7% year-over-year to -$747000.0; the TTM figure through Mar 2026 stood at -$3.1 billion (down 11837.81% YoY), while the FY2025 annual figure was -$696.0 million, down 703091.92% from the prior year.
• Profit After Tax improved to -$747000.0 in Q1 2026 per VOR's latest filing, from -$696.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $92.3 million in Q4 2023 and bottomed at -$1.6 billion in Q2 2025.
• Historically, Profit After Tax has averaged -$185.2 million across 5 years, with a median of -$23.9 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 486.01% — and 2025, when it plunged 9256976.47%.
• Vor Biopharma's Profit After Tax stood at -$23.9 million in 2022, then surged by 486.01% to $92.3 million in 2023, then decreased by 6.65% to $86.2 million in 2024, then plunged by 907.78% to -$696.0 million in 2025, then soared by 99.89% to -$747000.0 in 2026.
• Business Quant data shows VOR's Profit After Tax at -$747000.0 in Q1 2026, -$696.0 million in Q4 2025, and -$812.7 million in Q3 2025.